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J32-microglobulin; a new form of amyloid protein associated with
chronic hemodialysis. Carpal tunnel syndrome (CTS) has been associ-
ated with amyloid deposits and is now regarded as a major complication
in chronic hemodialysis patients. While this new syndrome has been
receiving increasing attention, its etiology has not been clarified. We
have isolated amyloid fibrils from amyloid laden tissues inside the
carpal tunnel in four different hemodialysis patients with CTS. After
solubilization in guanidine HCI, a significant amount of the protein was
located in a homogeneous, low molecular weight fraction. Each protein
was found to he identical to 2-microglobulin with regard to its
molecular weight of 11,000 on SDS-PAGE, amino acid composition and
N-terminal amino acids: Ile-Gln-Arg-Thr-Pro-Lys-lle-Gln-Val-Tyr-Ser-
Arg-His-Pro-Ala-Glu. In direct immunofluorescent study, anti-2-mi-
croglobulin did react positively with amyloid deposits. These results
demonstrate that the amyloid associated with chronic hemodialysis
contains as major component a new form of amyloid fibril protein that
is homologous to p-microglobulin. It is postulated that 2-microglob-
ulin cannot be removed from the blood by conventional hemodialysis,
and accumulates in tissues causing the formation of amyloid fibrils,
which, having a relatively high affinity to the carpal tunnel area, thus
causes CTS.
Carpal tunnel syndrome (CTS) has recently been recognized
increasingly in patients under chronic hemodialysis [1—111. A
significant correlation exists between the duration of dialysis
treatment and the incidence of CTS [9—11]. This syndrome
therefore has been regarded as an important complication of
chronic hemodialysis. Our observations have been made, like
other groups [3, 6—121, of frequent amyloid deposits in the
carpal tunnel synovia, tendon and ligaments, suggesting that
amyloid deposits play a causative role in CTS.
Biochemical analyses of amyloid proteins over the last ten
years show several different forms of amyloid related to the
clinical classification [13], Protein AL, which is of immunoglob-
ulin origin, was identified as the amyloid fibril protein of
primary and myeloma—associated amyloidosis. Secondary
amyloidosis associated with chronic inflammatory diseases has
deposits that are composed of amyloid A (AA), a degradation
product of an acute phase reactant, serum AA. Aprealbumin
constitutes amyloid fibrils of familial amyloidotic polyneu-
ropathy and a certain type of senile cardiac amyloidosis.
Aprecaicitonin is the amyloid protein of medullary carcinoma of the
thyroid. Gamma trace is the identified protein of hereditary
amyloidotic angiopathy [141, and a "novel" protein is present in
the cerebrovascular amyloid in Alzheimer's disease [15].
To our knowledge, however, no studies on the nature of
amyloid fibril protein in hemodialysis—associated amyloidosis
have been reported except our recent preliminary report [16].
We report here four different cases of hemodialysis—associ-
ated amyloidosis with CTS, in which /32-microglobulin was
identified as a new form of amyloid protein.
Methods
Patients
Four patients with end—stage renal failure treated with regular
hemodialysis had undergone surgical treatment for carpal tun-
nel syndrome. The clinical background of the patients is sum-
marized in Table I. No patient had a history of amyloidosis,
diabetes, rheumatoid arthritis, systemic lupus erythematosus,
multiple myeloma or tuberculosis. At operation, white colored
amyloid—rich nodules were obtained from the perineurium of
the median nerve or synovium inside the carpal tunnel in each
patient. Wet weights of the tissues ranged from 0.5 to 2.0 g.
Existence of amyloid deposits in the materials was confirmed
by staining red with Congo—red and green birefringence by use
of a polarizing microscope, accounting for 60 to 90% of the
tissues. All patients had experienced relief of pain and pares-
thetic symptom due to carpal tunnel syndrome after operation.
Twenty patients without any sign of carpal tunnel syndrome
who had been treated with hemodialysis for more than ten years
(average 12.6 years) were selected from Niigata University
Hospital and the affiliated hospitals in order to compare the
serum levels of /32-microglohulin with those in the four afore-
mentioned patients. Each hemodialysis treatment was carried
out for five hours using a disposable cuprophane dialyzer in a
single—pass system.
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Isolation and fractionation of amyloid fibrils
Amyloid fibrils were purified by repeated homogenization in
0.1 M phosphate—buffered saline (PBS), pH 7.1, and then in
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Table 1. Clinical features in the four patients of hemodialysis—associated amyloidosis with CTS
Cause of Duration of
No. Patient Age Sex renal failure hemodialysis (years) CTS*
I S.S. 48 F chronic glomerulonephritis 13 S/C
2 U.S. 31 M chronic glomerulonephritis 8 S
3 T.N. 54 F chronic glomerulonephritis 14 S/C
4 K.I. 44 M chronic glomerulonephritis 12 S
* Symbol is S, shunt side; C, controlateral side.
distilled water, by the methods of Pras et al [17] and Glenner,
Harada and Isersky [18]. The lyophilized amyloid fibril concen-
trates were solubilized with 6 M guanidine HCI, buffered to pH
7.6 with 0.1 M Tris-HCI containing 0.01 M ethylenediamine-
tetraacetate (EDTA), and were allowed to stand with intermit-
tent stirring for 12 hours at room temperature. The solutions
were chromatographed on a column (0.75 x 60 cm) of TSK-
GEL 03000 SW (Toyo Soda Manufacturing Co., Ltd., Tokyo,
Japan) using a Hitachi Model 638-30 liquid chromatograph
(Tokyo, Japan). HPLC was carried out at 25°C with 4 M
guanidine HCI buffered to pH 7.6 with 0.1 M Tris-HCI contain-
ing 0.01 M EDTA. The flow rate was 0.5 mllmin and the eluate
was monitored by measuring absorbance at 280 nm.
SDS-polyacrylamide gel electrophoresis
Molecular weights of the proteins of the peaks were deter-
mined by SDS-polyacrylamide--gel electrophoresis (PAGE) ac-
cording to the modified method of Laemmli [19] as described
previously 1201, using 1.0 mm thick gradient [8 to 18%] slab gel.
Bovine serum albumin (Mr 67,000), actin (Mr41,700), carbonic
anhydrase (Mr 28,700), myoglobin (Mr 17,200) and a cyanogen
bromide fragment of myoglobin (Mr 8,270) were used as stan-
dards for the estimation of molecular weights.
Amino acid analysis and sequence determination
The amyloid proteins were hydrolyzed in 6 N HCI in evacu-
ated sealed tubes at 110°C for 24 hours. The amino acids were
analyzed on a Hitachi 835 automated amino acid analyzer. The
N-terminal sequence determination was performed using a
gas/liquid phase model 470 A sequencer (Applied Biosystem
Inc., USA). Phenylthiohydantoin amino acids were identified
with HPLC (type LC-4A, Shimazu, Japan) on a Unisil QCI8
column using a gradient system of acetonitril in sodium acetate
buffer, p11 4.6.
Immunofluorescent study
Direct immunofluorescent staining was done using FITC-
conjugated rabbit immunoglobulin against human 2-microg1ob-
ulin (DAKO Immunoglobulins a/s, Copenhagen, Denmark).
The monospecificity of the antibody was confirmed by forma-
tion of a single precipitin line on Ouchterlony double diffusion
against human serum, and by loss of the reactivity on double
diffusion and immunohistochemistry, after absorption with pu-
rified human 2-microglobulin. Sections of amyloid rich nodules
that had been snap—frozen in dry ice acetone and stored at
-80°C were prepared on a cryostat (Bright Instrument Com-
pany Limited, England). Frozen sections cut at ito 3 sm thick
were overlaid for 30 mm at room temperature with the FITC-
conjugated antibodies. Stained sections were examined by an
incident—type fluorescent photo—microscope (type BH-2, Olym-
pus, Japan). Sections of all specimens were treated with FITC-
conjugated antibodies against human immunoglobulins: kappa
chains, IgG, IgA, 1gM, and C3 and fibrinogen (Behringwerke
AG, Marburg, West Germany), as controls for the staining
procedure.
Radioimmunoassay
Serum concentrations of I3rmicroglobulin were measured by
radioimmunoassay (Phadebas 132-micro test, Pharmacia, Upp-
sala, Sweden).
Results
Although the amounts of tissues obtained from the operations
for CTS in the four patients were not large, the content of
amyloid protein in the each tissue was barely enough for
determination of N-terminal sequence. Extracts of the PBS-
insoluble materials with distilled water showed strongly posi-
tive Congo-red stainings, indicating the existence of many
amyloid fibrils. All isolated native amyloid fibrils were positive
for polarization birefringence after staining with Congo-red.
After solubilization of the fibrils in 6 M guanidine HCI, the
solution was applied on a column of TSK-GEL G3000SW, and
a similar pattern of elution was obtained from each fibrils
preparation isolated from four patients (Fig. 1). From all
preparations, single major protein peaks were obtained at the
same elution volume as indicated by bars in Figure 1. SDS-
PAGE of the each major peak from HPLC showed a main band
with an apparent Mr = 11,000 plus a few minor bands of a small
amount of contaminants (Fig. 2). The major peaks were used for
the present analyses without further purification because the
amount of each sample was exceedingly limited. Table 2 shows
the results of amino acid analysis of each major peak from
HPLC. Each amino acid composition of the sample was very
similar to that of normal human f32-microglobuiin, although
some variation were noticed in Glu, Gly, Ala, Tyr and Lys.
The results of N-terminal sequence analysis of the four
preparations are shown in Table 3. The first steps in all samples
gave a mixture of amino acids including lie. In the first step of
patient No. I (S.S.), a few amino acids, of which lie was the
major one, were detected. In each subsequent step, however,
only one amino acid was detected and sixteen residues of
N-terminal amino acids could be determined. In patient No. 2
(U.S.) fourteen residues except in the first step could he
identified. In patient No. 3 (T.N.) the residues in the first to
fourth step could not be determined because of high levels of
back ground amino acids. However, after fifth step seven
residues were identified. In the sample from patient No. 4
(K.I.), fifteen residues except in the first, second and fourteenth
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tured amyloid fibril proteins from patient No. I (S.S.); (B, C, D, E)
Elution volume, ml major protein peaks of!, 2, 3 and 4 obtained from HPLC in Fig. I,
Fig. 1. The elution profiles ofa,nyloidfibril proteins from four different
patients on a column of TSK 3000SW equilibrated with 4 M guanidine
HCI. The major fractions of the 11,000 M protein peaks were indicated
respectively; (M) standards proteins: I bovine serum alburnin,2 actin,
3 carbonic anhvdrase, 4 myoglobin and 5 cyanogen bromide fragment
qf lObi1i.
by bars. I: Patient No. 1 (S.S.), 2: Patient No. 2 (U.S.), 3: Patient No.
3 (TN.), 4: Patient No. 4 (K.T.).
steps were identified. All residues analyzed and identified in the
four different samples were identical among themselves and
completely homologous with the known j32-microglobulin Se-
Table 2. Amino acid compositiona of the amyloid proteins from four
different patients compared with /32-microglobulin
— ——
quence.
Direct immunofluorescent studies on a piece of amyloid rich
tissues snap—frozen at the time of operation for CTS demon-
strated strong depositions of p,-microglobulin in the areas
corresponding to those of Congo—red positive staining (Fig. 3).
The amyloid deposits in the all carpal tissues obtained from the
four patients showed positive reactions with anti-human 13r
microglobulin. Control stainings with antiserum to IgG, IgA,
1gM, kappa chains, C5 and fibrinogen showed negative results
in the same sections. Diagnostic rectal biopsy was performed in
three out of the four patients. In the rectal specimens, amyloid
depositions were also observed in the walls of small blood
vessels. The amyloid in the all rectal specimens showed the
same immunohistochemical characteristics as those of the
amyloid in the carpal tissues.
Serum levels of 2-microglobuiin in the four patients ranged
from 40.7 to 48.5 mg/liter (M SD: 43.6 3.3 mg/liter),
significantly higher than the normal values 1.2 0.6 mg/liter
a Expressed in residues per mole of protein
b Calculated from sequence data [22]
"ND, not determined
(P < 0.001). We also measured the serum concentrations of
132-microglobulin in 20 patients under chronic hemodialysis
without any signs of CTS. There was no difference between the Discussion
serum levels of 2-microglobulin from the four patients and
those from 20 patients (Table 4). Serum levels of 32-microglob- The present investigation demonstrated that the protein pres-
ulin in both groups increased slightly during five hour ent in amyloid fibrils in hemodialysis—associated amyloidosis
hemodialysis. This was a significant difference (P <0.001). from four different patients is related to 2-microglobulin, by
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Table 3. The amino terminal amino acid sequences of amyloid proteins from four patientsa
No. Patient N-terminal sequence
I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
I S.S. lie —Gin— Arg—Thr— Pro —Lys—Ile —Gin— Val —Tyr— Ser —Arg— His —Pro—Ala —Glu—
2 U.S. [ J—Gln—Arg—Thr—Pro—Lys—Ile —Gln—Val—Tyr—Ser—Arg—His —Pro—
3 TN. [ 3 —[ 3— [ I —[ 3—Pro —Lys— lie —Gin— Val —Tyr— Ser —
4 K.1. F I—Gin-- Arg —Thr— Pro —Lys— lie —Gin— Val—Tyr— Ser —Arg— His —Pro—Ala —
f32microglobulin22 lie —Gin— Arg —Thr— Pro —Lys— lie —Gin-- Va! —Tyr— Ser —Arg— His —Pro— Ala —Glu—
a Undetermined or equivocal residues are indicated by brackets.
Table 4. Serum )32-microgiohulin levels in the study groups
Groups studied
Serum /32-m(M SD icrogiobulinmg/liter)
Pre-dialysis Post-dialysis
Normal subjects (N 20) 1.2 0.6 —
Patients with CTS (N = 4) 43.6 3.3 52.3 4.2
Patients without CTS (N = 20) 44.1 4.8 5L8 5.8
Fig. 3. Congo red—hematoxylin, A, and immunofluorescent; B, stains
of the tissue obtained at carpal tunnel release operation from patient
No. 2 (U.S.). Congo red—stained amyloid demonstrates characteristic
green birefringence, whereas the rest of the tissue shows whitish
birefringence primarily attributed to collagen, A. Direct immunoflu-
orescent stain of the same area as A with anti-J32-microglobulin shows
positive stain to the amyloid, B. (x50)
employing both chemical and immunolluorescent analyses.
Each amyloid protein obtained from four patients contained
single methionyl residue, which (32-microglobulin molecule con-
tains at the C-terminal position. It was also shown that all the
proteins were eiuted in the same elution volume on HPLC and
had the same molecular weight of 11,000 on SDS-PAGE. These
features all indicate that the hemodialysis—associated amyloid
must be f32-microglobulin molecule per Se, not fragments of the
protein.
(32-Microglobulin is a low—molecular weight protein (M =
11,800) present, in small amount, in normal human serum and
body fluids [21]. The complete amino acid sequence [223 dis-
closed the striking homology of the amino acid sequence to that
of the various homology region of IgG. Analysis of the
three—dimensional structure by x-ray crystallography demon-
Strates that almost half of amino acid residues in j32-microglob-
ulin participate in large (3-structures [23], which are one of the
essential properties of amyloid protein [133. Since serum 132-
microglobulin molecules pass through the glomerular mem-
branes and are normally reabsorbed to a large extent in kidney
tubules where they are catabolized, increased serum concen-
trations of this protein are well known in patients with end-stage
kidney disease.
In agreement with the observations of other investigators [24,
25], our results revealed markedly increased levels of 132-
microglobulin in the plasma of hemodialysis patients as com-
pared with levels of the protein in the plasma of normal
subjects. It seems to be due to hemoconcentration that plasma
132-microglobulin levels of post-dialysis were higher than those
of pre-dialysis. Our results confirmed that conventional
hemodialysis, using the cuprophane membrane dialyzer, cannot
remove /32-microglobulin from the blood as expected on the
basis of its molecular weight. It is now of particular importance
because of uremic toxicity that f32-microglobulin is a non-
dialyzable substance and accumulates in the tissues of hemodi-
alysis patients, causing the formation of amyloid fibrils.
Serum levels of f32-microglobulin in the four patients were
compared with those in 20 patients without CTS. No difference
has been observed in serum levels of /32-microglobulin between
both groups. Therefore, serum levels might not be useful for a
marker for hemodialysis—associated amyloidosis, and it is likely
that some, unknown as yet (such as an amyloid—enhancing)
factor plays a role in formation of amyloid fibrils. However, one
may believe that prolonged elevation of serum levels of /32-
microglobulin should be most important pathogenically.
Carpal tunnel syndrome as a major complication in hemodi-
alysis patients first attracted public attention about a decade ago
[I], and an increased incidence of CTS has been recently
reported [2—121. While the rates vary considerably, it can be
stated that CTS occurs in more than 10% of the patients under
hemodialysis treatment over ten years.
Kachel et al [71 have observed amyloid deposits in 11 of 13
patients dialysed for eight years or more and operated on for
.t. "r:•, -
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CTS. Certain groups [11, 12] have also reported high incidence
of the amyloid deposits in synovia and tendon inside carpal
tunnel in the patients with CTS, but other groups [6, 8—11]
rarely or never observed amyloid deposits and doubted whether
amyloid deposits played a causative role in CTS. Our four
patients presented in this paper showed massive amyloid de-
posits in the tissues inside carpal tunnel, which had created
compression of the median nerve. According to these observa-
tions, we are justified to claim that amyloidosis plays an
important role in the etiology of CTS in hemodialysis patients.
Carpal tunnel syndrome has been known to be associated with
some cases of AL amyloidosis (primary and myeloma—associ-
ated) and of familial amyloidosis [261. But, there are no estab-
lished cases of CTS associated with AA type of secondary
amyloidosis. It is of particular interest to note that the amyloid
proteins of AL-amyloidosis and hemodialysis—associated (/32-
microglobulin) amyloidosis are both related to immunoglobulin
domain, and both of these have a tendency to develop CTS.
As to whether the involvement of the hemodialysis—associ-
ated amyloidosis was localized or systemic, different opinions
have been expressed. Schwarz et al [91 emphasized that
amyloid deposits in hemodialysis—associated CTS corresponds
to the localized form. On the other hand, Kachel et al [7],
Charra et al [111, and Altmeyer, Kachel and Rurine [28] have
demonstrated amyloid deposition in various tissues such as
perineural tissue, skin, rectum and bone [29—33]. The facts that
three out of our four patients had amyloid deposits in the
rectum indicate a distinct possibility of its systemic involve-
ment and more serious nature. In the respect that the amyloi-
dosis is apparently caused by chronic hemodialysis treatment,
this amyloidosis is secondary in clinical classification. All
secondary amyloidosis analyzed so far are AA-type, and there-
fore hemodialysis—associated amyloidosis related to /32-micro-
globulin is suggested to be a new type of secondary
amyloidosis.
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